OPPM
ALXN

Opus Point Partners Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Opus Point Partners Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$973K Buy
9,933
+6
+0.1% +$676 1.76% 11
2019
Q2 		$1.3M Hold
9,927
– – 1.92% 8
2019
Q1 		$1.34M Sell
9,927
-560
-5% -$69.6K 1.82% 10
2018
Q4 		$1.02M Sell
10,487
-2,360
-18% -$279K 2.25% 12
2018
Q3 		$1.79M Sell
12,847
-887
-6% -$111K 4.26% 6
2018
Q2 		$1.71M Sell
13,734
-119
-0.9% -$13.9K 3.7% 5
2018
Q1 		$1.54M Buy
13,853
+4,295
+45% +$513K 3.03% 8
2017
Q4 		$1.14M Sell
9,558
-1,889
-17% -$230K 0.99% 31
2017
Q3 		$1.61M Buy
11,447
+1,921
+20% +$261K 1.44% 28
2017
Q2 		$1.16M Sell
9,526
-9,175
-49% -$1.07M 1.06% 34
2017
Q1 		$2.27M Sell
18,701
-6,272
-25% -$809K 1.68% 28
2016
Q4 		$3.06M Buy
24,973
+402
+2% +$49.2K 2.43% 17
2016
Q3 		$3.01M Buy
24,571
+7,270
+42% +$936K 1.69% 21
2016
Q2 		$2.02M Sell
17,301
-8,104
-32% -$1.15M 1.95% 24
2016
Q1 		$3.54M Sell
25,405
-7,564
-23% -$1.11M 2.73% 13
2015
Q4 		$6.29M Sell
32,969
-52
-0.2% -$9.08K 4.15% 4
2015
Q3 		$5.16M Buy
33,021
+11,547
+54% +$2.11M 2.85% 5
2015
Q2 		$3.88M Sell
21,474
-557
-3% -$96.1K 3.07% 17
2015
Q1 		$3.82M Buy
22,031
+3,699
+20% +$670K 3.2% 15
2014
Q4 		$3.39M Buy
+18,332
New +$3.4M 3.36% 10

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Opus Point Partners Management's ALXN Position: Q3 2019 in Review

Opus Point Partners Management increased its Alexion Pharmaceuticals (ALXN) stake by 0.06% in Q3 2019, buying an estimated $676 and bringing the position to 9,933 shares worth $973K. The position accounts for 1.76% of the portfolio, ranked #11.

Opus Point Partners Management first reported a position in ALXN in Q4 2014 and has held it in 20 quarters since. The position peaked at $6.29M in Q4 2015. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Opus Point Partners Management held 9,933 shares of Alexion Pharmaceuticals worth $973K as of Q3 2019.
  • Opus Point Partners Management bought 6 Alexion Pharmaceuticals shares in Q3 2019, an estimated $676.
  • Alexion Pharmaceuticals made up 1.76% of Opus Point Partners Management's portfolio in Q3 2019, its #11 holding.
  • Opus Point Partners Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Opus Point Partners Management's Alexion Pharmaceuticals position peaked at $6.29M in Q4 2015.
  • 647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.